4.8 Article

Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 117, 期 5, 页码 1361-1369

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI29470

关键词

-

资金

  1. NCI NIH HHS [R01 CA 94037, R01 CA094037] Funding Source: Medline
  2. NHLBI NIH HHS [T32 HL072739, T32 HL 072739] Funding Source: Medline
  3. NIAID NIH HHS [T32 AI007525, P01 AI 50514, P01 AI050514, T32 AI 07525] Funding Source: Medline
  4. NIDDK NIH HHS [DK 63608, R01 DK 70999, R56 DK070999, R01 DK070999, P30 DK063608] Funding Source: Medline

向作者/读者索取更多资源

We have developed a model of autoimmunity to investigate autoantibody-mediated cross-presentation of self antigen. RIP-mOVA mice, expressing OVA in pancreatic beta cells, develop severe autoimmune diabetes when given OT-I cells (OVA-specific CD8(+) T cells) and anti-OVA IgG but not when given T cells alone. Anti-OVA IgG is not directly injurious to the islets but rather enhances cross-presentation of apoptotic islet antigen to the OT-I cells, leading to their differentiation into potent effector cells. Antibody-driven effector T cell activation is dependent on the presence of activating Fc receptors for IgG (Fc gamma Rs) and cross-priming DCs. As a consequence, diabetes incidence and severity was reduced in mice lacking activating Fc gamma Rs. An intact complement pathway was also required for disease development, as C3 deficiency was also partially protective. C3-deficient animals exhibited augmented T cell priming overall, indicating a proinflammatory role for complement activation after the T cell priming phase. Thus, we show that autoreactive antibody can potently enhance the activation of effector T cells in response to cross-presented self antigen, thereby contributing to T cell-mediated autoimmunity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据